{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T01:28:37Z","timestamp":1787794117776,"version":"build-2784847793"},"reference-count":105,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004606","name":"Chang Gung Medical Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004606","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.bcp.2020.114137","type":"journal-article","created":{"date-parts":[[2020,7,4]],"date-time":"2020-07-04T18:22:36Z","timestamp":1593886956000},"page":"114137","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Overexpression of ABCB1 and ABCG2 contributes to reduced efficacy of the PI3K\/mTOR inhibitor samotolisib (LY3023414) in cancer cell lines"],"prefix":"10.1016","volume":"180","author":[{"given":"Chung-Pu","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Yu","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Lusvarghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang-Hui","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pin-Jung","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tai-Ho","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jau-Song","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suresh V.","family":"Ambudkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2020.114137_b0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.semcancer.2019.07.009","article-title":"PI3K\/Akt\/mTOR inhibitors in cancer: At the bench and bedside","author":"Alzahrani","year":"2019","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.bcp.2020.114137_b0010","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S1368-7646(02)00120-6","article-title":"Activation of the PI3K\/Akt pathway and chemotherapeutic resistance","volume":"5","author":"West","year":"2002","journal-title":"Drug Resist Updat."},{"key":"10.1016\/j.bcp.2020.114137_b0015","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.advenzreg.2006.01.004","article-title":"Roles of the RAF\/MEK\/ERK and PI3K\/PTEN\/AKT pathways in malignant transformation and drug resistance","volume":"46","author":"McCubrey","year":"2006","journal-title":"Adv. Enzyme Regul."},{"key":"10.1016\/j.bcp.2020.114137_b0020","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.stem.2009.01.007","article-title":"PTEN\/PI3K\/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells","volume":"4","author":"Bleau","year":"2009","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.bcp.2020.114137_b0025","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s00280-012-2043-3","article-title":"Overcoming acquired resistance to anticancer therapy: focus on the PI3K\/AKT\/mTOR pathway","volume":"71","author":"Burris","year":"2013","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.bcp.2020.114137_b0030","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1158\/1535-7163.MCT-13-0639","article-title":"Picking the point of inhibition: a comparative review of PI3K\/AKT\/mTOR pathway inhibitors","volume":"13","author":"Dienstmann","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bcp.2020.114137_b0035","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrclinonc.2018.28","article-title":"Targeting the PI3K pathway in cancer: are we making headway?","volume":"15","author":"Janku","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bcp.2020.114137_b0040","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1007\/s40265-019-01161-6","article-title":"First global approval","volume":"79","author":"Alpelisib","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.bcp.2020.114137_b0045","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1042\/BST20140034","article-title":"Anticipating mechanisms of resistance to PI3K inhibition in breast cancer: a challenge in the era of precision medicine","volume":"42","author":"Leroy","year":"2014","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.bcp.2020.114137_b0050","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1146\/annurev.med.53.082901.103929","article-title":"Mechanisms of cancer drug resistance","volume":"53","author":"Gottesman","year":"2002","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.bcp.2020.114137_b0055","first-page":"219","article-title":"Targeting multidrug resistance in cancer","volume":"5","author":"Szakacs","year":"2006","journal-title":"Nat. Rev."},{"key":"10.1016\/j.bcp.2020.114137_b0060","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/s41568-018-0005-8","article-title":"Revisiting the role of ABC transporters in multidrug-resistant cancer","volume":"18","author":"Robey","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bcp.2020.114137_b0065","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/978-1-60761-416-6_4","article-title":"Mechanisms of multidrug resistance in cancer","volume":"596","author":"Gillet","year":"2010","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.bcp.2020.114137_b0070","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.drudis.2007.12.010","article-title":"The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME-Tox)","volume":"13","author":"Szakacs","year":"2008","journal-title":"Drug Discovery Today"},{"key":"10.1016\/j.bcp.2020.114137_b0075","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1023\/A:1012866803188","article-title":"Overview: ABC transporters and human disease","volume":"33","author":"Gottesman","year":"2001","journal-title":"J. Bioenerg. Biomembr."},{"key":"10.1016\/j.bcp.2020.114137_b0080","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1126\/science.1099314","article-title":"EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy","volume":"304","author":"Paez","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.bcp.2020.114137_b0085","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1124\/jpet.110.167601","article-title":"Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux","volume":"334","author":"Agarwal","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bcp.2020.114137_b0090","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1124\/dmd.118.084210","article-title":"Brain distribution of a panel of epidermal growth factor receptor inhibitors using cassette dosing in wild-type and Abcb1\/Abcg2-deficient mice","volume":"47","author":"Kim","year":"2019","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bcp.2020.114137_b0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104297","article-title":"Brain accumulation of osimertinib and its active metabolite AZ5104 is restricted by ABCB1 (P-glycoprotein) and ABCG2 (breast cancer resistance protein)","volume":"146","author":"van Hoppe","year":"2019","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bcp.2020.114137_b0100","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1124\/jpet.111.190488","article-title":"Brain distribution of cediranib is limited by active efflux at the blood-brain barrier","volume":"341","author":"Wang","year":"2012","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bcp.2020.114137_b0105","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1124\/jpet.112.192195","article-title":"Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on the brain distribution of a novel BRAF inhibitor: vemurafenib (PLX4032)","volume":"342","author":"Mittapalli","year":"2012","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bcp.2020.114137_b0110","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.bcp.2012.11.003","article-title":"Overexpression of ATP-binding cassette transporter ABCG2 as a potential mechanism of acquired resistance to vemurafenib in BRAF(V600E) mutant cancer cells","volume":"85","author":"Wu","year":"2013","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2020.114137_b0115","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.phrs.2017.11.006","article-title":"P-glycoprotein (MDR1\/ABCB1) and breast cancer resistance protein (BCRP\/ABCG2) affect brain accumulation and intestinal disposition of encorafenib in mice","volume":"129","author":"Wang","year":"2018","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bcp.2020.114137_b0120","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1124\/jpet.118.253708","article-title":"Brain distribution and active efflux of three panRAF inhibitors: considerations in the treatment of melanoma brain metastases","volume":"368","author":"Gampa","year":"2019","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bcp.2020.114137_b0125","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1158\/1535-7163.MCT-15-0553","article-title":"Efficacy of PARP inhibitor rucaparib in orthotopic glioblastoma xenografts is limited by ineffective drug penetration into the central nervous system","volume":"14","author":"Parrish","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bcp.2020.114137_b0130","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s11095-014-1442-z","article-title":"Breast cancer resistance protein (BCRP\/ABCG2) and P-glycoprotein (P-GP\/ABCB1) restrict oral availability and brain accumulation of the PARP inhibitor rucaparib (AG-014699)","volume":"32","author":"Durmus","year":"2015","journal-title":"Pharm. Res."},{"key":"10.1016\/j.bcp.2020.114137_b0135","doi-asserted-by":"crossref","first-page":"5236","DOI":"10.1021\/acs.molpharmaceut.8b00742","article-title":"ABCB1 attenuates the brain penetration of the PARP inhibitor AZD2461","volume":"15","author":"de Gooijer","year":"2018","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.bcp.2020.114137_b0140","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1124\/dmd.110.034256","article-title":"Role of P-glycoprotein and breast cancer resistance protein-1 in the brain penetration and brain pharmacodynamic activity of the novel phosphatidylinositol 3-kinase inhibitor GDC-0941","volume":"38","author":"Salphati","year":"2010","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bcp.2020.114137_b0145","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1021\/acs.molpharmaceut.5b00687","article-title":"Human ATP-binding cassette transporter ABCG2 confers resistance to CUDC-907, a dual inhibitor of histone deacetylase and phosphatidylinositol 3-kinase","volume":"13","author":"Wu","year":"2016","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.bcp.2020.114137_b0150","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1021\/acs.molpharmaceut.7b00277","article-title":"Overexpression of ATP-binding cassette subfamily G member 2 confers resistance to phosphatidylinositol 3-kinase inhibitor PF-4989216 in cancer cells","volume":"14","author":"Wu","year":"2017","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.bcp.2020.114137_b0155","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.1200\/JCO.2010.32.4962","article-title":"Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein","volume":"29","author":"Hofmeister","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcp.2020.114137_b0160","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1158\/1078-0432.CCR-13-1759","article-title":"P-glycoprotein, CYP3A, and plasma carboxylesterase determine brain and blood disposition of the mTOR Inhibitor everolimus (Afinitor) in mice","volume":"20","author":"Tang","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2020.114137_b0165","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1124\/jpet.119.258392","article-title":"CC-115, a dual mammalian target of rapamycin\/DNA-dependent protein kinase inhibitor in clinical trial, is a substrate of ATP-binding cassette G2, a risk factor for CC-115 resistance","volume":"371","author":"Beebe","year":"2019","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bcp.2020.114137_b0170","first-page":"8634","article-title":"Karyotypic complexity of the NCI-60 drug-screening panel","volume":"63","author":"Roschke","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2020.114137_b0175","doi-asserted-by":"crossref","first-page":"7762","DOI":"10.1016\/S0021-9258(19)57466-X","article-title":"Multiple drug-resistant human KB carcinoma cells independently selected for high-level resistance to colchicine, adriamycin, or vinblastine show changes in expression of specific proteins","volume":"261","author":"Shen","year":"1986","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2020.114137_b0180","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.bcp.2007.12.001","article-title":"Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R))","volume":"75","author":"Robey","year":"2008","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2020.114137_b0185","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1038\/sj.bjc.6601370","article-title":"Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity","volume":"89","author":"Robey","year":"2003","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bcp.2020.114137_b0190","first-page":"8","article-title":"Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes","volume":"59","author":"Miyake","year":"1999","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2020.114137_b0195","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1158\/1535-7163.MCT-07-0352","article-title":"New inhibitors of ABCG2 identified by high-throughput screening","volume":"6","author":"Henrich","year":"2007","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bcp.2020.114137_b0200","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1126\/science.3457471","article-title":"Human multidrug-resistant cell lines: increased mdr1 expression can precede gene amplification","volume":"232","author":"Shen","year":"1986","journal-title":"Science"},{"key":"10.1016\/j.bcp.2020.114137_b0205","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1177\/1087057105284576","article-title":"A high-throughput cell-based assay for inhibitors of ABCG2 activity","volume":"11","author":"Henrich","year":"2006","journal-title":"J. Biomol. Screen."},{"key":"10.1016\/j.bcp.2020.114137_b0210","doi-asserted-by":"crossref","first-page":"3287","DOI":"10.1158\/1535-7163.MCT-07-2005","article-title":"Evidence for dual mode of action of a thiosemicarbazone, NSC73306: a potent substrate of the multidrug resistance linked ABCG2 transporter","volume":"6","author":"Wu","year":"2007","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bcp.2020.114137_b0215","doi-asserted-by":"crossref","first-page":"3040","DOI":"10.1021\/acs.molpharmaceut.9b00274","article-title":"Avapritinib: a selective inhibitor of KIT and PDGFRalpha that reverses ABCB1 and ABCG2-mediated multidrug resistance in cancer cell lines","volume":"16","author":"Wu","year":"2019","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.bcp.2020.114137_b0220","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.bcp.2014.10.003","article-title":"Human ATP-Binding Cassette transporters ABCB1 and ABCG2 confer resistance to CUDC-101, a multi-acting inhibitor of histone deacetylase, epidermal growth factor receptor and human epidermal growth factor receptor 2","volume":"92","author":"Wu","year":"2014","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2020.114137_b0225","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.bcp.2013.08.004","article-title":"Human ABCB1 (P-glycoprotein) and ABCG2 mediate resistance to BI 2536, a potent and selective inhibitor of Polo-like kinase 1","volume":"86","author":"Wu","year":"2013","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2020.114137_b0230","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.bcp.2018.07.018","article-title":"Human ATP-binding cassette transporters ABCB1 and ABCG2 confer resistance to histone deacetylase 6 inhibitor ricolinostat (ACY-1215) in cancer cell lines","volume":"155","author":"Wu","year":"2018","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2020.114137_b0235","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s002320001020","article-title":"Functional characterization of glycosylation-deficient human P-glycoprotein using a vaccinia virus expression system","volume":"173","author":"Gribar","year":"2000","journal-title":"J. Membr. Biol."},{"key":"10.1016\/j.bcp.2020.114137_b0240","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1158\/0008-5472.CAN-03-3298","article-title":"Pheophorbide a is a specific probe for ABCG2 function and inhibition","volume":"64","author":"Robey","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2020.114137_b0245","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/S0076-6879(98)92039-0","article-title":"Drug-stimulatable ATPase activity in crude membranes of human MDR1-transfected mammalian cells","volume":"292","author":"Ambudkar","year":"1998","journal-title":"Methods Enzymol."},{"key":"10.1016\/j.bcp.2020.114137_b0250","doi-asserted-by":"crossref","first-page":"5010","DOI":"10.1021\/bi973045u","article-title":"Human P-glycoprotein exhibits reduced affinity for substrates during a catalytic transition state","volume":"37","author":"Ramachandra","year":"1998","journal-title":"Biochemistry"},{"key":"10.1016\/j.bcp.2020.114137_b0255","doi-asserted-by":"crossref","first-page":"8657","DOI":"10.1074\/jbc.M010044200","article-title":"Correlation between steady-state ATP hydrolysis and vanadate-induced ADP trapping in Human P-glycoprotein. Evidence for ADP release as the rate-limiting step in the catalytic cycle and its modulation by substrates","volume":"276","author":"Kerr","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2020.114137_b0260","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.pep.2019.03.002","article-title":"Large-scale purification of functional human P-glycoprotein (ABCB1)","volume":"159","author":"Nandigama","year":"2019","journal-title":"Protein Expr. Purif."},{"key":"10.1016\/j.bcp.2020.114137_b0265","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","article-title":"AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading","volume":"31","author":"Trott","year":"2010","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.bcp.2020.114137_b0270","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1126\/science.aav7102","article-title":"Structural insight into substrate and inhibitor discrimination by human P-glycoprotein","volume":"363","author":"Alam","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.bcp.2020.114137_b0275","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/nature22345","article-title":"Structure of the human multidrug transporter ABCG2","volume":"546","author":"Taylor","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2020.114137_b0280","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21010238","article-title":"The Selective class IIa histone deacetylase inhibitor TMP195 resensitizes ABCB1- and ABCG2-overexpressing multidrug-resistant cancer cells to cytotoxic anticancer drugs","volume":"21","author":"Wu","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2020.114137_b0285","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1158\/1535-7163.MCT-15-0996","article-title":"Characterization of LY3023414, a novel PI3K\/mTOR dual inhibitor eliciting transient target modulation to impede tumor growth","volume":"15","author":"Smith","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bcp.2020.114137_b0290","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.bbrc.2017.06.052","article-title":"Targeting PI3K-AKT-mTOR by LY3023414 inhibits human skin squamous cell carcinoma cell growth in vitro and in vivo","volume":"490","author":"Zou","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bcp.2020.114137_b0295","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1158\/1541-7786.MCR-16-0256","article-title":"Dual PI3K\/mTOR inhibition in colorectal cancers with APC and PIK3CA mutations","volume":"15","author":"Foley","year":"2017","journal-title":"Mol. Cancer Res. MCR"},{"key":"10.1016\/j.bcp.2020.114137_b0300","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1158\/1535-7163.MCT-11-0446","article-title":"GDC-0980 is a novel class I PI3K\/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway","volume":"10","author":"Wallin","year":"2011","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bcp.2020.114137_b0305","doi-asserted-by":"crossref","first-page":"7905","DOI":"10.1158\/0008-5472.CAN-08-0499","article-title":"Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2","volume":"68","author":"Dai","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2020.114137_b0310","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1016\/j.bcp.2012.02.028","article-title":"GW583340 and GW2974, human EGFR and HER-2 inhibitors, reverse ABCG2- and ABCB1-mediated drug resistance","volume":"83","author":"Sodani","year":"2012","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2020.114137_b0315","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.bcp.2012.06.019","article-title":"OSI-930 analogues as novel reversal agents for ABCG2-mediated multidrug resistance","volume":"84","author":"Kuang","year":"2012","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2020.114137_b0320","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/0005-2736(94)90190-2","article-title":"Calcein accumulation as a fluorometric functional assay of the multidrug transporter","volume":"1191","author":"Hollo","year":"1994","journal-title":"BBA"},{"key":"10.1016\/j.bcp.2020.114137_b0325","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1146\/annurev.pharmtox.39.1.361","article-title":"Biochemical, cellular, and pharmacological aspects of the multidrug transporter","volume":"39","author":"Ambudkar","year":"1999","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.bcp.2020.114137_b0330","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1006\/bbrc.2001.5130","article-title":"Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells","volume":"285","author":"Ozvegy","year":"2001","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bcp.2020.114137_b0335","doi-asserted-by":"crossref","first-page":"7468","DOI":"10.1038\/sj.onc.1206948","article-title":"P-glycoprotein: from genomics to mechanism","volume":"22","author":"Ambudkar","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.bcp.2020.114137_b0340","doi-asserted-by":"crossref","first-page":"21160","DOI":"10.1074\/jbc.272.34.21160","article-title":"Relation between the turnover number for vinblastine transport and for vinblastine-stimulated ATP hydrolysis by human P-glycoprotein","volume":"272","author":"Ambudkar","year":"1997","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2020.114137_b0345","doi-asserted-by":"crossref","first-page":"4808","DOI":"10.1158\/0008-5472.CAN-05-3322","article-title":"Selective toxicity of NSC73306 in MDR1-positive cells as a new strategy to circumvent multidrug resistance in cancer","volume":"66","author":"Ludwig","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2020.114137_b0350","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1038\/s41467-020-16155-2","article-title":"ABCG2 transports anticancer drugs via a closed-to-open switch","volume":"11","author":"Orlando","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2020.114137_b0355","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/SLA.0000000000001908","article-title":"PI3K\/mTOR dual inhibitor, LY3023414, demonstrates potent antitumor efficacy against esophageal adenocarcinoma in a rat model","volume":"266","author":"Zaidi","year":"2017","journal-title":"Ann. Surg."},{"key":"10.1016\/j.bcp.2020.114137_b0360","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1093\/jjco\/hyy011","article-title":"PI3K-mTOR pathway identified as a potential therapeutic target in biliary tract cancer using a newly established patient-derived cell panel assay","volume":"48","author":"Sakamoto","year":"2018","journal-title":"Jpn. J. Clin. Oncol."},{"key":"10.1016\/j.bcp.2020.114137_b0365","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.1158\/1078-0432.CCR-17-3421","article-title":"A first-in-human phase 1 study of LY3023414, an oral PI3K\/mTOR dual inhibitor, in patients with advanced cancer","volume":"24","author":"Bendell","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2020.114137_b0370","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1002\/cncr.32677","article-title":"Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway","volume":"126","author":"Rubinstein","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.bcp.2020.114137_b0375","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1186\/s12885-015-1514-4","article-title":"Enhanced efficacy of photodynamic therapy by inhibiting ABCG2 in colon cancers","volume":"15","author":"Kim","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bcp.2020.114137_b0380","first-page":"2137","article-title":"Protective role of ABCG2 against oxidative stress in colorectal cancer and its potential underlying mechanism","volume":"40","author":"Nie","year":"2018","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.bcp.2020.114137_b0385","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1124\/dmd.112.046052","article-title":"Preclinical assessment of the absorption and disposition of the phosphatidylinositol 3-kinase\/mammalian target of rapamycin inhibitor GDC-0980 and prediction of its pharmacokinetics and efficacy in human","volume":"40","author":"Salphati","year":"2012","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bcp.2020.114137_b0390","first-page":"1210","article-title":"Decreased affinity for efflux transporters increases brain penetrance and molecular targeting of a PI3K\/mTOR inhibitor in a mouse model of glioblastoma","volume":"17","author":"Becker","year":"2015","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.bcp.2020.114137_b0395","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1002\/ijc.2910630609","article-title":"High rate of MDR-1 and heterogeneous pattern of MRP expression without gene amplification in endometrial cancer","volume":"63","author":"Esteller","year":"1995","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bcp.2020.114137_b0400","first-page":"1377","article-title":"Advances in the molecular genetics of endometrial cancer (Review)","volume":"6","author":"Esteller","year":"1999","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.bcp.2020.114137_b0405","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.3892\/or.2013.2790","article-title":"Overcoming paclitaxel resistance in uterine endometrial cancer using a COX-2 inhibitor","volume":"30","author":"Hasegawa","year":"2013","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.bcp.2020.114137_b0410","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/cas.12612","article-title":"Expression of BAF57 in ovarian cancer cells and drug sensitivity","volume":"106","author":"Yamaguchi","year":"2015","journal-title":"Cancer Sci."},{"key":"10.1016\/j.bcp.2020.114137_b0415","first-page":"74","article-title":"Estrogen induces cell proliferation by promoting ABCG2-mediated efflux in endometrial cancer cells","volume":"16","author":"Yaguchi","year":"2018","journal-title":"Biochem. Biophys. Rep."},{"key":"10.1016\/j.bcp.2020.114137_b0420","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1002\/cmdc.201100543","article-title":"Tyrosine kinase inhibitors influence ABCG2 expression in EGFR-positive MDCK BCRP cells via the PI3K\/Akt signaling pathway","volume":"7","author":"Pick","year":"2012","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bcp.2020.114137_b0425","first-page":"1678","article-title":"The PI3K\/AKT signaling pathway regulates ABCG2 expression and confers resistance to chemotherapy in human multiple myeloma","volume":"41","author":"Wang","year":"2019","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.bcp.2020.114137_b0430","doi-asserted-by":"crossref","first-page":"39068","DOI":"10.1074\/jbc.M306362200","article-title":"Akt signaling regulates side population cell phenotype via Bcrp1 translocation","volume":"278","author":"Mogi","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2020.114137_b0435","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1124\/dmd.104.003228","article-title":"Regulation of the cell surface expression of human BCRP\/ABCG2 by the phosphorylation state of Akt in polarized cells","volume":"33","author":"Takada","year":"2005","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bcp.2020.114137_b0440","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1093\/carcin\/bgn223","article-title":"Analysis of ABCG2 expression and side population identifies intrinsic drug efflux in the HCC cell line MHCC-97L and its modulation by Akt signaling","volume":"29","author":"Hu","year":"2008","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.bcp.2020.114137_b0445","doi-asserted-by":"crossref","first-page":"455","DOI":"10.3892\/or.2016.4827","article-title":"Upregulation of ABCG2 via the PI3K-Akt pathway contributes to acidic microenvironment-induced cisplatin resistance in A549 and LTEP-a-2 lung cancer cells","volume":"36","author":"Hu","year":"2016","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.bcp.2020.114137_b0450","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.canlet.2013.04.006","article-title":"Inactivation of PTEN increases ABCG2 expression and the side population through the PI3K\/Akt pathway in adult acute leukemia","volume":"336","author":"Huang","year":"2013","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bcp.2020.114137_b0455","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s13075-018-1512-4","article-title":"Soluble uric acid increases PDZK1 and ABCG2 expression in human intestinal cell lines via the TLR4-NLRP3 inflammasome and PI3K\/Akt signaling pathway","volume":"20","author":"Chen","year":"2018","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.bcp.2020.114137_b0460","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ejphar.2017.09.001","article-title":"Dual effects of the PI3K inhibitor ZSTK474 on multidrug efflux pumps in resistant cancer cells","volume":"815","author":"Muthiah","year":"2017","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bcp.2020.114137_b0465","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0052898","article-title":"PI3K inhibition enhances doxorubicin-induced apoptosis in sarcoma cells","volume":"7","author":"Marklein","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.bcp.2020.114137_b0470","doi-asserted-by":"crossref","first-page":"248","DOI":"10.4149\/neo_2012_032","article-title":"Perifosine downregulates MDR1 gene expression and reverses multidrug-resistant phenotype by inhibiting PI3K\/Akt\/NF-kappaB signaling pathway in a human breast cancer cell line","volume":"59","author":"Lin","year":"2012","journal-title":"Neoplasma"},{"key":"10.1016\/j.bcp.2020.114137_b0475","doi-asserted-by":"crossref","first-page":"773","DOI":"10.3892\/or.2013.2520","article-title":"Inhibition of the PI3K\/Akt pathway increases the chemosensitivity of gastric cancer to vincristine","volume":"30","author":"Xie","year":"2013","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.bcp.2020.114137_b0480","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/aps.2016.121","article-title":"The PI3K\/mTOR dual inhibitor BEZ235 suppresses proliferation and migration and reverses multidrug resistance in acute myeloid leukemia","volume":"38","author":"Deng","year":"2017","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.bcp.2020.114137_b0485","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.lungcan.2012.07.005","article-title":"Inhibition of phosphoinositide-3 kinase pathway down regulates ABCG2 function and sensitizes malignant pleural mesothelioma to chemotherapy","volume":"78","author":"Fischer","year":"2012","journal-title":"Lung Cancer"},{"key":"10.1016\/j.bcp.2020.114137_b0490","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.3892\/or.2017.5879","article-title":"Cepharanthine hydrochloride reverses Pglycoprotein-mediated multidrug resistance in human ovarian carcinoma A2780\/Taxol cells by inhibiting the PI3K\/Akt signaling pathway","volume":"38","author":"Huang","year":"2017","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.bcp.2020.114137_b0495","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.3892\/ijo.2016.3423","article-title":"Timosaponin A-III reverses multi-drug resistance in human chronic myelogenous leukemia K562\/ADM cells via downregulation of MDR1 and MRP1 expression by inhibiting PI3K\/Akt signaling pathway","volume":"48","author":"Chen","year":"2016","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.bcp.2020.114137_b0500","doi-asserted-by":"crossref","first-page":"3659","DOI":"10.3892\/or.2016.4730","article-title":"Osthole shows the potential to overcome P-glycoproteinmediated multidrug resistance in human myelogenous leukemia K562\/ADM cells by inhibiting the PI3K\/Akt signaling pathway","volume":"35","author":"Wang","year":"2016","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.bcp.2020.114137_b0505","article-title":"Grape seed proanthocyanidin extract reverses multidrug resistance in HL-60\/ADR cells via inhibition of the PI3K\/Akt signaling pathway","volume":"125","author":"Lin","year":"2020","journal-title":"Biomed. Pharmacother. Biomed. Pharmacother."},{"key":"10.1016\/j.bcp.2020.114137_b0510","first-page":"6071","article-title":"(-)-Epigallocatechin-3-gallate down-regulates doxorubicin-induced overexpression of P-glycoprotein through the coordinate inhibition of PI3K\/Akt and MEK\/ERK signaling pathways","volume":"37","author":"Satonaka","year":"2017","journal-title":"Anticancer Res."},{"key":"10.1016\/j.bcp.2020.114137_b0515","doi-asserted-by":"crossref","first-page":"621","DOI":"10.2174\/138945011795378540","article-title":"Improving cancer chemotherapy with modulators of ABC drug transporters","volume":"12","author":"Shukla","year":"2011","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.bcp.2020.114137_b0520","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1002\/cncr.21227","article-title":"Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma","volume":"104","author":"Pusztai","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.bcp.2020.114137_b0525","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.dmpk.2017.02.003","article-title":"Metabolism of KO143, an ABCG2 inhibitor","volume":"32","author":"Liu","year":"2017","journal-title":"Drug Metab. Pharmacokinet."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295220303737?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295220303737?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T13:14:55Z","timestamp":1757769295000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295220303737"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":105,"alternative-id":["S0006295220303737"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2020.114137","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Overexpression of ABCB1 and ABCG2 contributes to reduced efficacy of the PI3K\/mTOR inhibitor samotolisib (LY3023414) in cancer cell lines","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2020.114137","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114137"}}